

Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle

Authorised

- Penethamate hydriodide
- Benethamine penicillin
- Framycetin sulfate

Product identification

Medicine name:

Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle

Active substance:

Penethamate hydriodide
Benethamine penicillin
Framycetin sulfate

Target species:

Cattle

Route of administration:

Intramammary use

Product details

Active substance and strength:

Penethamate hydriodide
100.00 milligram(s) / 1.00 Syringe
Benethamine penicillin
280.00 milligram(s) / 1.00 Syringe
Framycetin sulfate
100.00 milligram(s) / 1.00 Syringe

Pharmaceutical form:

Intramammary suspension

Withdrawal period by route of administration:

Intramammary use:

-

Cattle

- Meat and offal. 10 day
 - Milk. 37 day
-

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ51RC25

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Netherlands

Available in:

Netherlands

Package description:

Cardboard box or plastic container containing 120 single use intramammary syringes and 120 teat wipes (containing isopropanol 70%). Each 4.5 g syringe (cylinder with piston and cap, all made of low density polyethylene) contains 5 ml intramammary suspension.

Cardboard box or plastic container containing 60 single use intramammary syringes and 60 teat wipes (containing isopropanol 70%). Each 4.5 g syringe (cylinder with piston and cap, all made of low density polyethylene) contains 5 ml intramammary suspension.

Cardboard box or plastic container containing 20 single use intramammary syringes and 20 teat wipes (containing isopropanol 70%). Each 4.5 g syringe (cylinder with piston and cap, all made of low density polyethylene) contains 5 ml intramammary suspension.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:

8/11/1992

Manufacturing sites for batch release:

Haupt Pharma Latina S.r.l.

Lohmann Pharma Herstellung GmbH

Responsible authority:

Medicines Evaluation Board

Authorisation number:

REG NL 108011

Date of authorisation status change:

26/01/2022

Reference member state:

Ireland

Procedure number:

IE/V/0271/001

Concerned member states:

Belgium Bulgaria Czechia France Hungary Netherlands Poland Romania
Slovakia Slovenia United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics